Efficacy and Safety of Adjunctive Aripiprazole in Schizophrenia
Authors:
- Wei ZhengWZWei Zheng
- Ying-Jun ZhengYZYing-Jun Zheng
- Xian-Bin LiXLXian-Bin Li
- Yi-Lang TangYTYi-Lang Tang
- Chuan-Yue WangCWChuan-Yue Wang
- Ying-Qiang XiangYXYing-Qiang Xiang
- Jose de LeonJLJose de Leon
- 1 December 2016
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 36 (6) , 628-636
Abstract
This meta-analysis of randomized controlled trials (RCTs) evaluated the efficacy and safety of adding aripiprazole to other antipsychotics in schizophrenia. A systematic computer search identified 55 RCTs including 4457 patients who were randomized to aripiprazole (14.0 ± 7.0 mg/d) versus placebo (18 RCTs) or open antipsychotic treatment (37 RCTs). Aripiprazole significantly outperformed the comparison interventions based on psychiatric scales: (1) total score in 43 RCTs (N = 3351) with a standardized mean difference (SMD) of −0.48 (95% confidence interval [CI], −0.68 to −0.28; P < 0.00001; I 2 = 88%), (2) negative symptom score in 30 RCTs (N = 2294) with an SMD of −0.61(95% CI, −0.91 to −0.31; P < 0.00001; I 2 = 91%), and (3) general psychopathology score in 13 RCTs (N = 1138) with a weighted mean difference (WMD) of −4.02 (95% CI, −7.23 to −0.81; P = 0.01; I 2 = 99%), but not in positive symptoms in 29 RCTs (N = 2223) with a SMD of −0.01 (95% CI, 0.26 to 0.25; P = 0.95; I 2 = 88%). Differences in total score based on psychiatric scales may be explained by the use of an antipsychotic for comparison rather than placebo in 31 RCTs with a nonblind design. Aripiprazole outperformed the comparison interventions for body weight in 9 RCTs (N = 505) with a WMD of −5.08 kg (95% CI, −7.14 to −3.02; P < 0.00001; I 2 = 35%) and for body mass index (BMI) in 14 RCTs (N = 809) with a WMD of −1.78 (CI: −2.25 to −1.31; P < 0.00001; I 2 = 54%). The BMI meta-regression analysis indicated aripiprazole's association with lower BMI was stronger in females. Adjunctive aripiprazole appears safe but better RCTs are needed to demonstrate efficacy. Chinese journals and scientific societies should encourage the publication of high-quality RCTs and require registration in a centralized Chinese database.Keywords
This publication has 34 references indexed in Scilit:
- Effect of Aripiprazole on Cognitive Function and Hyperprolactinemia in Patients with Schizophrenia Treated with RisperidoneClinical Psychopharmacology and Neuroscience, 2013
- Dealing with clinical heterogeneity in meta‐analysis. Assumptions, methods, interpretationInternational Journal of Methods in Psychiatric Research, 2013
- Metabolic effects of adjunctive aripiprazole in clozapine‐treated patients with schizophreniaActa Psychiatrica Scandinavica, 2012
- Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature ReviewSchizophrenia Bulletin, 2011
- Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trialInternational Journal of Neuropsychopharmacology, 2010
- 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review GroupSpine, 2009
- Aripiprazole Augmentation in Clozapine-Treated Patients With Refractory SchizophreniaThe Journal of Clinical Psychiatry, 2008
- Dropout Rates in Randomized Clinical Trials of Antipsychotics: A Meta-analysis Comparing First- and Second-Generation Drugs and an Examination of the Role of Trial Design FeaturesSchizophrenia Bulletin, 2008
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?The Lancet, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986